{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:47:30Z","timestamp":1783446450527,"version":"3.55.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T00:00:00Z","timestamp":1736035200000},"content-version":"vor","delay-in-days":218,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007812","name":"University of Washington","doi-asserted-by":"publisher","award":["RG-1808-32345"],"award-info":[{"award-number":["RG-1808-32345"]}],"id":[{"id":"10.13039\/100007812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01CX002383"],"award-info":[{"award-number":["I01CX002383"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007268","name":"Washington University in St. Louis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006379","name":"Office of Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006379","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jns.2024.123041","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T15:15:26Z","timestamp":1715267726000},"page":"123041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Prevalence of anti-myelin oligodendrocyte glycoprotein antibodies across neuroinflammatory and neurodegenerative diseases"],"prefix":"10.1016","volume":"461","author":[{"given":"Ritu R.","family":"Trivedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela S.","family":"Archambault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarice","family":"Pavlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Gastaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Cantoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ghezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne H.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory F.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2024.123041_bb0005","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3390\/biom12040591","article-title":"Aquaporin-4 in Neuromyelitis Optica Spectrum disorders: a target of autoimmunity in the central nervous system","volume":"12","author":"Abe","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.jns.2024.123041_bb0010","article-title":"Clinical spectrum of inflammatory central nervous system demyelinating disorders associated with antibodies against myelin oligodendrocyte glycoprotein","volume":"130","author":"Akaishi","year":"2019","journal-title":"Neurochem. Int., Emerging focus areas in Neuroimmunology"},{"key":"10.1016\/j.jns.2024.123041_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105150","article-title":"Utility of the 2023 international MOGAD panel proposed criteria in clinical practice: an institutional cohort","volume":"81","author":"Alaboudi","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2024.123041_bb0020","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/ijms22010100","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: current insights into the disease pathophysiology, diagnosis and management","volume":"22","author":"Ambrosius","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jns.2024.123041_bb0025","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2024.123041_bb0030","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1007\/s10067-017-3724-4","article-title":"Autoantibodies against myelin sheath and S100\u03b2 are associated with cognitive dysfunction in patients with rheumatoid arthritis","volume":"36","author":"Baptista","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jns.2024.123041_bb0035","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJMoa022328","article-title":"Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event","volume":"349","author":"Berger","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2024.123041_bb0040","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/ana.21916","article-title":"Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease","volume":"66","author":"Brilot","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2024.123041_bb0045","doi-asserted-by":"crossref","first-page":"E1095","DOI":"10.1212\/WNL.0000000000201662","article-title":"Significance of myelin oligodendrocyte glycoprotein antibodies in CSF: a retrospective multicenter study","volume":"100","author":"Carta","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123041_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102399","article-title":"Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica","volume":"45","author":"Ciotti","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2024.123041_bb0055","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1093\/brain\/awaa309","article-title":"The microglial component of amyotrophic lateral sclerosis","volume":"143","author":"Clarke","year":"2020","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.jns.2024.123041_bb0060","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ana.24189","article-title":"Seroprevalence of autoantibodies against brain antigens in health and disease","volume":"76","author":"Dahm","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2024.123041_bb0065","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clim.2010.11.013","article-title":"Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases","volume":"138","author":"Di Pauli","year":"2011","journal-title":"Clin. Immunol. Orlando Fla"},{"key":"10.1016\/j.jns.2024.123041_bb0070","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1111\/ene.15321","article-title":"Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis","volume":"29","author":"Falzone","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2024.123041_bb0075","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/1352458517696597","article-title":"Multiple sclerosis: serum-derived exosomes express myelin proteins","volume":"24","author":"Galazka","year":"2018","journal-title":"Mult. Scler. Houndmills Basingstoke Engl."},{"key":"10.1016\/j.jns.2024.123041_bb0080","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1007\/s00415-020-10024-0","article-title":"Cell-based assays for the detection of MOG antibodies: a comparative study","volume":"267","author":"Gastaldi","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2024.123041_bb0085","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028977","article-title":"Experimental autoimmune encephalomyelitis (EAE) as animal models of multiple sclerosis (MS)","volume":"8","author":"Glatigny","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.jns.2024.123041_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228883","article-title":"Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides","volume":"15","author":"Graner","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.jns.2024.123041_bb0095","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1474-4422(22)00520-8","article-title":"MOGAD comes of age with new criteria","volume":"22","author":"Graus","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2024.123041_bb0100","doi-asserted-by":"crossref","first-page":"17071","DOI":"10.1038\/nrdp.2017.71","article-title":"Amyotrophic lateral sclerosis","volume":"3","author":"Hardiman","year":"2017","journal-title":"Nat. Rev. Dis. Primer"},{"key":"10.1016\/j.jns.2024.123041_bb0105","article-title":"Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients","volume":"7","author":"Held","year":"2021","journal-title":"Mult. Scler. J. - Exp. Transl. Clin."},{"key":"10.1016\/j.jns.2024.123041_bb0110","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"H\u00f6ftberger","year":"2020","journal-title":"Acta Neuropathol. (Berl.)"},{"key":"10.1016\/j.jns.2024.123041_bb0115","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123041_bb0120","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrneurol.2012.203","article-title":"B cells and antibodies in multiple sclerosis pathogenesis and therapy","volume":"8","author":"Krumbholz","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jns.2024.123041_bb0125","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1056\/NEJMoa063602","article-title":"Lack of association between Antimyelin antibodies and progression to multiple sclerosis","volume":"356","author":"Kuhle","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2024.123041_bb0130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1742-2094-7-79","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in HIV-1 associated neurocognitive disorder: a cross-sectional cohort study","volume":"7","author":"Lackner","year":"2010","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jns.2024.123041_bb0135","first-page":"12","article-title":"Serum aquaporin 4-immunoglobulin G titer and neuromyelitis optica spectrum disorder Activity and severity: a systematic review and meta-analysis","author":"Liu","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2024.123041_bb0140","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jalm\/jfab101","article-title":"Validation of a flow cytometry live cell-based assay to detect myelin oligodendrocyte glycoprotein antibodies for clinical diagnostics","volume":"7","author":"Lopez","year":"2022","journal-title":"J. Appl. Lab. Med."},{"key":"10.1016\/j.jns.2024.123041_bb0145","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jamaneurol.2020.3115","article-title":"Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G-associated disorder","volume":"77","author":"Lopez-Chiriboga","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2024.123041_bb0150","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/1521-4141(200207)32:7<1905::AID-IMMU1905>3.0.CO;2-L","article-title":"Critical role of antigen-specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein","volume":"32","author":"Lyons","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jns.2024.123041_bb0155","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jns.2024.123041_bb0160","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3233\/JAD-2011-110221","article-title":"Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias","volume":"26","author":"Maetzler","year":"2011","journal-title":"J. Alzheimers Dis. JAD"},{"key":"10.1016\/j.jns.2024.123041_bb0165","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41586-020-2625-x","article-title":"C9orf72 in myeloid cells suppresses STING-induced inflammation","volume":"585","author":"McCauley","year":"2020","journal-title":"Nature"},{"issue":"183","key":"10.1016\/j.jns.2024.123041_bb0170","first-page":"4067","article-title":"Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis","volume":"1950","author":"McLaughlin","year":"2009","journal-title":"J. Immunol. Baltim. Md"},{"key":"10.1016\/j.jns.2024.123041_bb0175","first-page":"191","article-title":"Auto-antibodies against proteins of spinal cord cells in cerebrospinal fluid of patients with amyotrophic lateral sclerosis (ALS)","volume":"44","author":"Niebroj-Dobosz","year":"2006","journal-title":"Folia Neuropathol."},{"key":"10.1016\/j.jns.2024.123041_bb0180","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/jnnp-2020-323158","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire","volume":"91","author":"O'Connell","year":"2020","journal-title":"UK. J. Neurol. Neurosurg. Psychiatry"},{"issue":"194","key":"10.1016\/j.jns.2024.123041_bb0185","first-page":"5077","article-title":"B cell antigen presentation is sufficient to drive neuroinflammation in an animal model of multiple sclerosis","volume":"1950","author":"Parker Harp","year":"2015","journal-title":"J. Immunol. Baltim. Md"},{"key":"10.1016\/j.jns.2024.123041_bb0190","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1093\/brain\/awab231","article-title":"MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response","volume":"144","author":"Pellerin","year":"2021","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.jns.2024.123041_bb0195","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.expneurol.2014.05.015","article-title":"Glial cells in amyotrophic lateral sclerosis","volume":"262PB","author":"Philips","year":"2014","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jns.2024.123041_bb0200","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1212\/WNL.0b013e318228c0b1","article-title":"Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis","volume":"77","author":"Pr\u00f6bstel","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123041_bb0205","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12974-015-0256-1","article-title":"Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype","volume":"12","author":"Pr\u00f6bstel","year":"2015","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jns.2024.123041_bb0210","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/brain\/122.11.2047","article-title":"Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study","volume":"122","author":"Reindl","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.jns.2024.123041_bb0215","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jns.2024.123041_bb0220","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jamaneurol.2021.0912","article-title":"Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing","volume":"78","author":"Sechi","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2024.123041_bb0225","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2024.123041_bb0230","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1074\/jbc.RA118.004825","article-title":"CNS-derived extracellular vesicles from superoxide dismutase 1 (SOD1)G93A ALS mice originate from astrocytes and neurons and carry misfolded SOD1","volume":"294","author":"Silverman","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jns.2024.123041_bb0235","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000257","article-title":"Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis","volume":"3","author":"Spadaro","year":"2016","journal-title":"Neurol. - Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.jns.2024.123041_bb0240","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.25291","article-title":"Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein","volume":"84","author":"Spadaro","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2024.123041_bb0245","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood\u2013brain barrier breakdown in Alzheimer's disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jns.2024.123041_bb0250","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41582-021-00487-8","article-title":"Non-neuronal cells in amyotrophic lateral sclerosis - from pathogenesis to biomarkers","volume":"17","author":"Vahsen","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jns.2024.123041_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101416","article-title":"Role of B cells and antibodies in multiple sclerosis","volume":"36","author":"Wanleenuwat","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2024.123041_bb0260","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2024.123041_bb0265","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.jns.2024.123041_bb0270","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418762083","article-title":"Defining distinct features of anti-MOG antibody associated central nervous system demyelination","volume":"11","author":"Weber","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jns.2024.123041_bb0275","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0165-5728(94)90162-7","article-title":"Monoclonal and polyclonal antibody responses to the myelin basic protein epitope present in human urine","volume":"52","author":"Whitaker","year":"1994","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2024.123041_bb0280","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.165373","article-title":"MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity","volume":"8","author":"Yandamuri","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.jns.2024.123041_bb0285","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4103\/2152-7806.169561","article-title":"A comprehensive review of amyotrophic lateral sclerosis","volume":"6","author":"Zarei","year":"2015","journal-title":"Surg. Neurol. Int."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2400176X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2400176X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:30:15Z","timestamp":1736184615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X2400176X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":57,"alternative-id":["S0022510X2400176X"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.123041","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of anti-myelin oligodendrocyte glycoprotein antibodies across neuroinflammatory and neurodegenerative diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.123041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123041"}}